Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

O. Kalous · SciRah

Researcher profile · Semantic Scholar

O. Kalous

Share profile

O. Kalous — researcher profile on SciRah

h-index: 14
Works: 37
Citations: 2,223

Most-cited papers

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
R. Finn, J. Dering, D. Conklin, O. Kalous +8 more
2009Breast Cancer Research1,346 citations Open access
Semantic Scholar
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
N. O'Brien, K. McDonald, L. Tong, E. von Euw +9 more
2014Clinical Cancer Research120 citations Open access
Semantic Scholar
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
T. Frgala, O. Kalous, R. T. Proffitt, C. Reynolds
2007Molecular Cancer Therapeutics97 citations Open access
Semantic Scholar
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
N. O'Brien, D. Conklin, R. Beckmann, Tong Luo +9 more
2018Molecular Cancer Therapeutics87 citations
Semantic Scholar
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
O. Kalous, D. Conklin, Amrita J. Desai, N. O'Brien +8 more
2012Molecular Cancer Therapeutics78 citations Open access
Semantic Scholar
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Z. Wainberg, A. Anghel, A. M. Rogers, Amrita J. Desai +8 more
2013Molecular Cancer Therapeutics74 citations Open access
Semantic Scholar
Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity
Theresa M. Harned, O. Kalous, A. Neuwelt, J. Loera +5 more
2008Clinical Cancer Research65 citations Open access
Semantic Scholar
DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.
N. Keshelava, T. Frgala, J. Krejsa, O. Kalous +1 more
2005Methods in Molecular Medicine64 citations
Semantic Scholar
Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex
B. Maurer, O. Kalous, D. Yesair, Xia-Qin Wu +9 more
2007Clinical Cancer Research63 citations
Semantic Scholar
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
S. Hurvitz, O. Kalous, D. Conklin, Amrita J. Desai +8 more
2015Breast Cancer Research and Treatment53 citations
Semantic Scholar
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
M. Fejzo, L. Anderson, E. von Euw, O. Kalous +5 more
2013International Journal of Molecular Sciences48 citations Open access
Semantic Scholar
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma
H. Fang, Theresa M. Harned, O. Kalous, V. Maldonado +2 more
2011Clinical Cancer Research42 citations Open access
Semantic Scholar
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi
M. Fejzo, L. Anderson, Hsiao-Wang Chen, Enrique Guandique +3 more
2017Genes, Chromosomes and Cancer29 citations
Semantic Scholar
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
O. Kalous, D. Conklin, Amrita J. Desai, J. Dering +10 more
2013Breast Cancer Research and Treatment27 citations
Semantic Scholar
Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents.
R. Finn, A. Lau, O. Kalous, D. Conklin +8 more
20098 citations
Semantic Scholar
Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy
N. O'Brien, D. Conklin, Tong Luo, Raul Ayala +10 more
20175 citations
Semantic Scholar
Inhibition of HSP 90 with AUY 922 Induces Synergy in HER 2-Ampli fi ed Trastuzumab-Resistant Breast andGastric Cancer
Z. Wainberg, A. Anghel, A. M. Rogers, Amrita J. Desai +8 more
20135 citations
Semantic Scholar
Abstract P4-08-01: PI3K/mTOR inhibition overcomesin vitroandin vivotrastuzumab resistance independent of feedback activation of pAKT
N. O'Brien, K. McDonald, L. Tong, E. von Euw +9 more
20123 citations
Semantic Scholar
Panobinostat (LBH589), a pan-DAC inhibitor, induces cell death in ER+ and HER2 amplified cell lines in vitro and is synergistic in vivo with trastuzumab.
R. Finn, W. Shao, J. Dering, C. Ginther +7 more
20093 citations
Semantic Scholar
Abstract 3008: Preclinical characterization of AMG 900, a pan-aurora kinase inhibitor, alone and in combination with taxanes in ovarian cancer
O. Kalous, D. Conklin, Kanthinh Manivong, W. Wayne +11 more
20162 citations
Semantic Scholar
Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer
N. O'Brien, D. Conklin, Tong Luo, O. Kalous +5 more
20161 citations
Semantic Scholar
Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
O. Kalous, D. Conklin, Amrita J. Desai, N. O'Brien +8 more
20121 citations
Semantic Scholar
Abstract LB-70:In vitroanti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel of human breast cancer cell lines
C. Britten, Lucy Chow, D. Conklin, O. Kalous +7 more
20101 citations
Semantic Scholar
Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
C. Knights, Lucy C. Riches, A. Lau, Ramu Mangena +9 more
20091 citations
Semantic Scholar
Identification of predictive markers of response in colorectal cancer following treatment with dasatinib, an orally active tyrosine kinase inhibitor of ABL and SRC
Z. Wainberg, Judy Dering, C. Ginther, A. Anghel +6 more
20081 citations
Semantic Scholar
557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer
M. O'Connor, A. Lau, R. Finn, C. Knights +6 more
20081 citations
Semantic Scholar
Abstract P3-04-15: The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER+ breast cancer cell line xenografts
N. O'Brien, D. Conklin, Tong Luo, Raul Ayala +8 more
20170 citations
Semantic Scholar
Abstract P4-14-25: Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines
N. O'Brien, C. Nichols, J. Thomas, D. Conklin +6 more
20160 citations
Semantic Scholar
Abstract 3668: Inhibition of HSP90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer
Z. Wainberg, A. M. Rogers, N. O'Brien, A. Anghel +6 more
20120 citations
Semantic Scholar
P1-12-03: Combined Targeting of the PI3K Pathway and HER2 Overcomes Acquired and De Novo Trastuzumab Resistance.
N. O'Brien, K. McDonald, E. E. Von, D. Conklin +4 more
20110 citations
Semantic Scholar
Abstract P6-15-13: Biologic Activity of a Novel Heat Shock Protein 90 Inhibitor, PF-4928473, in Human Breast Cancer Cell Lines
R. Tsang, D. Conklin, O. Kalous, Amrita J. Desai +5 more
20100 citations
Semantic Scholar
PD 0332991, a selective CDK 4/6 inhibitor, preferentially inhibits proliferation of luminal ER+ breast cancer cells and acts synergistically with tamoxifen and trastuzumabin vitro.
R. Finn, J. Dering, David J Cohen, D. Conklin +4 more
20090 citations
Semantic Scholar
SodiumThiosulfateAdministered Six Hours after Cisplatin Does Not CompromiseAntineuroblastoma Activity
Theresa M. Harned, O. Kalous, A. Neuwelt, J. Loera +6 more
20080 citations
Semantic Scholar
Eficacy of periocular carboplatin in a xenograft model of vitreous seeding human retinoblastoma.
R. D. De Carvalho, M. Taban, O. Kalous, P. Reynolds +2 more
20040 citations
Semantic Scholar
The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents
O. Kalous, J. Krejsa, T. Frgala, C. Reynolds
20040 citations
Semantic Scholar
Pre-Clinical Testing of Chemotherapy Combinations in Retinoblastoma Cell Lines Using the Dimscan Cytotoxicity Assay
O. Kalous, J. Watanabe, A. Murphree, C. Reynolds
20030 citations
Semantic Scholar
[High-dose busulfan--monitoring plasma levels and dosage adjustments in adults].
O. Kalous, J. Mayer, L. Malášková
2001Casopis lekaru ceskych0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Conklin×25
Invite
D. Conklin — researcher profile on SciRah
R. Finn×20
Invite
R. Finn — researcher profile on SciRah
D. Slamon×18
Invite
D. Slamon — researcher profile on SciRah
N. O'Brien×14
Invite
N. O'Brien — researcher profile on SciRah

Amrita J. Desai

×13

Invite

Amrita J. Desai — researcher profile on SciRah

Invite

C. Ginther — researcher profile on SciRah

Invite

S. Hurvitz — researcher profile on SciRah

Invite

J. Dering — researcher profile on SciRah

Invite

E. von Euw — researcher profile on SciRah

Invite

C. Reynolds — researcher profile on SciRah

Invite

D. Slamon — researcher profile on SciRah

Invite

L. Anderson — researcher profile on SciRah